Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Measuring therapeutic efficacy in patients with Alzheimer's disease: role of instruments.

Riepe MW, Janetzky W, Lemming OM.

Dement Geriatr Cogn Disord. 2011;31(3):233-8. doi: 10.1159/000326214.

PMID:
21474932
2.
3.

Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.

Hellweg R, Wirth Y, Janetzky W, Hartmann S.

Int J Geriatr Psychiatry. 2012 Jun;27(6):651-6. doi: 10.1002/gps.2766.

PMID:
22513699
4.

Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study.

Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C; Memantine Lombardy Study Group..

Drugs Aging. 2009;26(4):321-32. doi: 10.2165/00002512-200926040-00003.

PMID:
19476399
6.

A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine.

Rüther E, Glaser A, Bleich S, Degner D, Wiltfang J.

Pharmacopsychiatry. 2000 May;33(3):103-8.

PMID:
10855461
7.
8.

Memantine in moderate-to-severe Alzheimer's disease.

Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group..

N Engl J Med. 2003 Apr 3;348(14):1333-41.

9.

Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease.

Heinen-Kammerer T, Rulhoff H, Nelles S, Rychlik R.

Clin Drug Investig. 2006;26(6):303-14. Review.

PMID:
17163264
10.
11.

A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease.

Schmitt F, Ryan M, Cooper G.

Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):135-41. Review.

PMID:
17269900
12.

Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli.

Kubová Z, Kremláček J, Vališ M, Szanyi J, Langrová J, Vít F, Kuba M.

J Clin Neurophysiol. 2010 Oct;27(5):334-40. doi: 10.1097/WNP.0b013e3181f413cb.

PMID:
20844442
13.

[Efficacy of memantine in the treatment of Alzheimer's disease].

Molinuevo Guix JL, Lladó Plarrumaní A.

Neurologia. 2005 Dec;20(10):686-91. Review. Spanish.

PMID:
16317590
14.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group..

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
15.

Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.

Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.

Dement Geriatr Cogn Disord. 2007;23(5):301-6.

PMID:
17356273
16.

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ.

Dement Geriatr Cogn Disord. 2007;24(1):20-7.

17.

Memantine in the treatment of dementia.

Maggiore C, Locatelli L, Grandi FC, Pizzolato G; Cochrane Neurological Network..

Neuroepidemiology. 2007;28(2):118-9. No abstract available.

PMID:
17409774
18.

Measuring treatment response in Alzheimer's disease clinical trials.

Caban-Holt A, Bottiggi K, Schmitt FA.

Geriatrics. 2005 Jun;Suppl:3-8. Review.

PMID:
16025769
19.

Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.

Pomara N, Ott BR, Peskind E, Resnick EM.

Alzheimer Dis Assoc Disord. 2007 Jan-Mar;21(1):60-4.

PMID:
17334274
20.

Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.

Bullock R.

Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. Review.

PMID:
16493232
Items per page

Supplemental Content

Support Center